Chinese Academy of Medical Sciences COVID-19 vaccine

Chinese Academy of Medical Sciences COVID-19 vaccine
Vaccine description
TargetSARS-CoV-2
Vaccine typeInactivated
Clinical data
Other namesCovidful (Chinese: 科维福; pinyin: Kēwéifú)
Routes of
administration		Intramuscular
Legal status
Legal status
  • Emergency authorization: China [1]
Identifiers
CAS Number
DrugBank
Part of a series on the
COVID-19 pandemic
Timeline
2019
2020
2021
2022
2023
Locations
By country and territory
By conveyance
International response
National responses
Medical response
Vaccines
Current vaccines
Variants
Variants of concern
Other variants
Economic impact and recession
By country
By sport
Impacts
Long COVID
Society
Politics
COVID-19 portal

Chinese Academy of Medical Sciences COVID-19 vaccine, or IMBCAMS COVID-19 vaccine, traded as Covidful (Chinese: 科维福; pinyin: Kēwéifú), is a COVID-19 vaccine developed by Institute of Medical Biology, Chinese Academy of Medical Sciences.

Clinical trials

In May 2020, Covidful started phase I/II clinical trial with 942 participants in China.[3]

In January 2021, Covidful started phase III clinical trials with 34,020 from Brazil and Malaysia.[4]

Authorizations

  Full authorization
  Emergency authorization
  Allowed for travel
See also: List of COVID-19 vaccine authorizations § Chinese Academy of Medical Sciences

On 9 June 2021, The vaccine has been approved by the Chinese authorities.[1]

References

  1. ^ a b Liu R, Woo R (9 June 2021). "China builds new plant for IMBCAMS COVID-19 vaccine -state media". Reuters. Retrieved 15 June 2021.
  2. ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
  3. ^ Clinical trial number NCT04412538 for "Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19" at ClinicalTrials.gov
  4. ^ Clinical trial number NCT04659239 for "The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19" at ClinicalTrials.gov
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.